背景:甲状腺是一种内分泌腺,对人体的一般代谢有影响。因此,甲状腺的分泌物可以改变整个身体的整体代谢。甲状腺功能减退症的患病率正在迅速增加,富裕国家的比率为2%-5%,印度为11%。被诊断为甲状腺功能减退症的人需要终生服药,造成巨大的压力。因此,进行这方面的研究势在必行。
目的:本研究旨在评估治疗性灌肠(KsharBasti)和口服KanchanarGuggul治疗甲状腺功能减退症的有效性。
方法:试验组(n=45)将接受治疗性灌肠(KsharBasti),然后口服阿育吠陀药物180天。对照组(n=45)将以1.6µg/kg/天的剂量给予左甲状腺素片,持续时间相同。目的是检查治疗前后甲状腺刺激激素(TSH)水平的变化。
结果:血清TSH与初始值的偏差超过20%,同时保留三碘甲状腺原氨酸(T3),甲状腺素(T4)水平在正常范围内,将被认为具有统计学意义。因此,我们预计治疗性灌肠和KanchanarGuggul治疗之间的血清TSH水平存在统计学上的显著差异.目前,药物准备工作正在进行中。我们预计将在2024年6月开始招募患者,在2025年12月进行数据分析,并在2026年初获得结果,标志着该试验的结束。
结论:本研究将评估治疗性灌肠的疗效,特别是KsharBasti,治疗甲状腺功能减退症。此外,更多的研究可以确定治疗性灌肠(KsharBasti)治疗妊娠期明显的甲状腺功能减退症和甲状腺功能减退症的疗效。
背景:临床试验注册印度CTRI/2023/05/052389;https://ctri。nic.在/临床试验/pmaindet2。php?EncHid=Nzk1NjY=&Enc=&userName=052389。
■PRR1-10.2196/57287。
BACKGROUND: The thyroid gland is an endocrine gland that has an impact on the body\'s general metabolism. Thus, the secretions of the thyroid gland can modify the overall metabolism of the entire body. The prevalence of hypothyroidism is increasing quickly, with rates of 2%-5% in affluent countries and 11% in India. Individuals diagnosed with hypothyroidism need to take medication for the rest of their lives, resulting in significant stress. Therefore, conducting a study in this area is imperative.
OBJECTIVE: This study aims to assess the effectiveness of the therapeutic
enema (Kshar Basti) and oral Kanchanar Guggul in the treatment of hypothyroidism.
METHODS: The trial group (n=45) will receive a therapeutic
enema (Kshar Basti) followed by oral Ayurvedic drugs for 180 days. The control group (n=45) will be given levothyroxine tablets at a dosage of 1.6 µg/kg/day for the same duration. The objective is to examine the alterations in thyroid stimulating hormone (TSH) levels before and after the treatment.
RESULTS: Any deviation of the serum TSH by more than 20% from the initial values, while keeping triiodothyronine (T3), and thyroxine (T4) levels within the normal range, will be deemed statistically significant. Consequently, we anticipate a statistically significant variation in serum TSH levels between the therapeutic
enema and Kanchanar Guggul treatments. Presently, the drug preparation operations are in progress. We expect to start enrolling patients in June 2024, do data analysis in December 2025, and acquire results by early 2026, marking the end of this trial.
CONCLUSIONS: This study will evaluate the efficacy of the therapeutic
enema, specifically Kshar Basti, in treating hypothyroidism. Furthermore, more research can determine the efficacy of a therapeutic
enema (Kshar Basti) in treating overt hypothyroidism and hypothyroidism during pregnancy.
BACKGROUND: Clinical Trials Registry India CTRI/2023/05/052389; https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=Nzk1NjY=&Enc=&userName=052389.
UNASSIGNED: PRR1-10.2196/57287.